FGFR1 and laryngotracheoesophageal cleft: However, the clinical results of these selective FGFR-TKIs were somewhat disappointing with overall responses of ~10%.11 Therefore, the therapeutic potential of FGFR inhibition in FGFR1-amplified LC will remain uncertain until more comprehensive understanding of FGFR pathway addiction is achieved.